The following analysis of BioNTech SE's expected performance over the next 3 months is based on a systematic, AI-powered analysis of their financial statement. In addition, numerous significant general factors and ratios were also utilized. First, analysis of the balance sheet factors outperformed the market benchmark. Second, the income statement factors beat expectation and over-performed the market benchmark in this time frame. Moreover, cash flow metrics beat expectation and over-performed their benchmark. Fourth, the most impactful financial ratios indicate that in the near term the company's growth will just keep up with their benchmark. All in all, our bottom line evaluation of BioNTech SE received the score of 93.
BioNTech SE reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was EUR 6,362.2 million compared to EUR 2,027.5 million a year ago. Revenue was EUR 6,374.6 million compared to EUR 2,048.4 million a year ago. Net income was EUR 3,698.8 million compared to EUR 1,128.1 million a year ago. Basic earnings per share from continuing operations was EUR 15.13 compared to EUR 4.64 a year ago. Diluted earnings per share from continuing operations was EUR 14.24 compared to EUR 4.39 a year ago.
Business Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
Sector Overview
BioNTech SE is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. BioNTech SE's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Parameter | Value | Change | Score | |
---|---|---|---|---|
Free Cashflow | 4.92 | 352% | 98 | |
Cashflow | 1,402.16 | 311% | 84 | |
Asset Turnover | 1.76 | 15% | 81 | |
Price to Book | 6.61 | -21% | 81 | |
Return on Equity | 155.47 | 16% | 45 |
* All values are TTM
The below chart reflects BioNTech SE's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While BioNTech SE's peer average final assessment score stands on 64, BioNTech SE's score is 93.
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. BioNTech SE's stock is now priced above its 5-day and 50-day, but below its 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a positive setup in both the short and medium-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), BioNTech SE's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 57.
Probing the balance sheet focused our attention on certain key numbers that provide meaningful signals for the near term. Its important to point out that balance sheet factors are responsible for up to 26.5% of the chances of the company to beat its benchmark performance during the upcoming quarter. First, assessing a drill down into the company's debt service capabilities shows exceptional overperformance related to cash and cash equivalents. Generally, the debt service capabilities factors impact up to 6.2% of a company's likelihood to over-perform the market. In addition, BioNTech SE's assets reveals mediocre developments going into assets changes. The strength of a company's assets affect up to 7.8% of the chances of the company to over-perform. Looking deeper into their debt structure suggests impressive results in terms of liabilities movement. Historically, the debt structure factors influence approximately up to 7.8% of the likelihood that the company will beat the market. Focusing on their suggests mediocre momentum in terms of shareholders' equity and intangible assets adjustments. Intangible assets and technical changes historically contribute up to 4.7% of the chances of a company to beat the market for the near term. With all factors taken together, the company's balance sheet warranted the score of 81.
Parameter | Value | Change | Score |
---|---|---|---|
Assets | 14,232.6 | 56% | 71 |
Capital Expenditure | -110.79 | -23% | 52 |
Cash & Equivalents | 2,392.7 | 162% | 96 |
Equity | 8,711.5 | 59% | 71 |
Liabilities | 5,521.1 | 51% | 96 |
The below chart describes BioNTech SE's performance as reflected on its balance sheet with respect to its peers. While BioNTech SE received a balance sheet score of 81, the average of its peers stands on 69.
Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Capital Expenditure Growth | Balance Sheet | mc_sort | Hidden |
---|---|---|---|---|---|---|---|---|---|
Amgen Inc. | 130.0B | 65 | 73 | 85 | 94 | 56 | 81 | 0 | 1 |
Gilead Sciences, Inc. | 78.2B | 61 | 78 | 72 | 55 | 81 | 78 | 1 | 1 |
Regeneron Pharmaceuticals, Inc. | 69.6B | 58 | 63 | 60 | 92 | 81 | 68 | 2 | 1 |
Vertex Pharmaceuticals Incorporated | 63.1B | 69 | 72 | 93 | 74 | 95 | 84 | 3 | 1 |
Biogen Inc. | 29.2B | 91 | 79 | 84 | 54 | 87 | 87 | 4 | 1 |
Seagen Inc. | 25.0B | 96 | 72 | 48 | 92 | 82 | 79 | 5 | 1 |
Horizon Therapeutics Public Limited Company | 20.8B | 61 | 74 | 62 | 88 | 56 | 74 | 6 | 1 |
Incyte Corporation | 16.6B | 82 | 71 | 73 | 81 | 86 | 80 | 7 | 1 |
Alnylam Pharmaceuticals, Inc. | 15.3B | 79 | 73 | 45 | 90 | 53 | 73 | 8 | 1 |
BioMarin Pharmaceutical Inc. | 14.4B | 85 | 66 | 60 | 64 | 69 | 69 | 9 | 1 |
BeiGene, Ltd. | 13.7B | 71 | 71 | 46 | 46 | 50 | 63 | 10 | 1 |
Exact Sciences Corporation | 9.2B | 71 | 71 | 55 | 45 | 54 | 66 | 11 | 1 |
United Therapeutics Corporation | 8.3B | 66 | 68 | 61 | 64 | 54 | 66 | 12 | 1 |
Neurocrine Biosciences, Inc. | 8.0B | 74 | 52 | 64 | 51 | 46 | 53 | 13 | 1 |
Exelixis, Inc. | 6.4B | 72 | 71 | 58 | 83 | 57 | 72 | 14 | 1 |
Sarepta Therapeutics, Inc. | 5.8B | 44 | 75 | 42 | 61 | 91 | 66 | 15 | 1 |
Halozyme Therapeutics, Inc. | 5.6B | 56 | 60 | 97 | 79 | 54 | 70 | 16 | 1 |
Ionis Pharmaceuticals, Inc. | 5.1B | 51 | 75 | 58 | 81 | 95 | 74 | 17 | 1 |
Ascendis Pharma A/S | 4.6B | 97 | 71 | 56 | 94 | 46 | 77 | 18 | 1 |
Apellis Pharmaceuticals, Inc. | 4.2B | 37 | 71 | 65 | 76 | 97 | 70 | 19 | 1 |
Novavax, Inc. | 4.1B | 74 | 73 | 42 | 60 | 66 | 67 | 20 | 1 |
Ultragenyx Pharmaceutical Inc. | 3.6B | 75 | 65 | 49 | 42 | 50 | 59 | 21 | 1 |
Cytokinetics, Incorporated | 3.6B | 92 | 70 | 64 | 95 | 43 | 77 | 22 | 1 |
Arrowhead Pharmaceuticals, Inc. | 3.3B | 40 | 64 | 52 | 40 | 46 | 51 | 23 | 1 |
Natera, Inc. | 3.3B | 63 | 71 | 60 | 92 | 43 | 71 | 24 | 1 |
Blueprint Medicines Corporation | 3.3B | 51 | 95 | 48 | 74 | 42 | 82 | 25 | 1 |
Mirati Therapeutics, Inc. | 3.2B | 38 | 73 | 51 | 53 | 64 | 62 | 26 | 1 |
Vir Biotechnology, Inc. | 3.0B | 96 | 72 | 67 | 64 | 41 | 75 | 27 | 1 |
ACADIA Pharmaceuticals Inc. | 2.7B | 48 | 74 | 62 | 37 | 95 | 68 | 28 | 1 |
PTC Therapeutics, Inc. | 2.3B | 96 | 71 | 52 | 77 | 60 | 75 | 29 | 1 |
Insmed Incorporated | 2.2B | 82 | 49 | 44 | 57 | 59 | 49 | 30 | 1 |
SpringWorks Therapeutics, Inc. | 1.9B | 89 | 72 | 49 | 80 | 45 | 72 | 31 | 1 |
Myriad Genetics, Inc. | 1.8B | 40 | 67 | 56 | 95 | 37 | 62 | 32 | 1 |
Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 72 | 61 | 84 | 37 | 73 | 33 | 1 |
BioCryst Pharmaceuticals, Inc. | 1.6B | 84 | 74 | 44 | 63 | 56 | 70 | 34 | 1 |
ChemoCentryx, Inc. | 1.4B | 76 | 69 | 54 | 85 | 71 | 72 | 35 | 1 |
IVERIC bio, Inc. | 1.2B | 41 | 71 | 55 | 97 | 74 | 69 | 36 | 1 |
Agios Pharmaceuticals, Inc. | 1.2B | 51 | 71 | 81 | 38 | 97 | 71 | 37 | 1 |
Prometheus Biosciences, Inc. | 1.1B | 43 | 74 | 51 | 58 | 43 | 62 | 38 | 1 |
Enanta Pharmaceuticals, Inc. | 1.0B | 91 | 77 | 48 | 98 | 94 | 84 | 39 | 1 |
Lyell Immunopharma, Inc. | 982.1M | 48 | 63 | 50 | 43 | 79 | 55 | 40 | 1 |
BridgeBio Pharma, Inc. | 977.7M | 39 | 70 | 80 | 38 | 40 | 63 | 41 | 1 |
Sana Biotechnology, Inc. | 941.0M | 97 | 62 | 43 | 41 | 65 | 60 | 42 | 1 |
FibroGen, Inc. | 927.4M | 46 | 64 | 70 | 46 | 52 | 59 | 43 | 1 |
ImmunoGen, Inc. | 844.7M | 48 | 75 | 61 | 73 | 95 | 74 | 44 | 1 |
Instil Bio, Inc. | 816.4M | 94 | 69 | 56 | 37 | 51 | 66 | 45 | 1 |
Syndax Pharmaceuticals, Inc. | 793.4M | 87 | 73 | 43 | 76 | 74 | 73 | 46 | 1 |
Chinook Therapeutics, Inc. | 770.8M | 57 | 72 | 46 | 48 | 38 | 60 | 47 | 1 |
Erasca, Inc. | 706.8M | 78 | 71 | 76 | 96 | 37 | 78 | 48 | 1 |
Deciphera Pharmaceuticals, Inc. | 705.9M | 84 | 72 | 44 | 40 | 50 | 65 | 49 | 1 |
Replimune Group, Inc. | 700.1M | 80 | 75 | 52 | 50 | 53 | 70 | 50 | 1 |
Nkarta, Inc. | 678.6M | 87 | 73 | 56 | 97 | 80 | 80 | 51 | 1 |
Verve Therapeutics, Inc. | 668.1M | 97 | 72 | 50 | 38 | 77 | 71 | 52 | 1 |
Anavex Life Sciences Corp. | 664.9M | 86 | 75 | 50 | 64 | 74 | 75 | 53 | 1 |
Gossamer Bio, Inc. | 642.4M | 88 | 73 | 42 | 41 | 57 | 67 | 54 | 1 |
IGM Biosciences, Inc. | 619.2M | 75 | 72 | 43 | 42 | 90 | 67 | 55 | 1 |
Design Therapeutics, Inc. | 607.9M | 96 | 73 | 55 | 64 | 37 | 73 | 56 | 1 |
AnaptysBio, Inc. | 595.6M | 63 | 71 | 54 | 72 | 66 | 69 | 57 | 1 |
Sangamo Therapeutics, Inc. | 589.7M | 52 | 69 | 52 | 75 | 66 | 65 | 58 | 1 |
Humacyte, Inc. | 553.1M | 66 | 70 | 80 | 71 | 68 | 78 | 59 | 1 |
Geron Corporation | 547.3M | 69 | 72 | 47 | 39 | 37 | 61 | 60 | 1 |
Intercept Pharmaceuticals, Inc. | 531.3M | 56 | 76 | 97 | 38 | 95 | 81 | 61 | 1 |
Bicycle Therapeutics plc | 514.4M | 92 | 70 | 54 | 88 | 65 | 76 | 62 | 1 |
Centessa Pharmaceuticals plc | 507.7M | 89 | 75 | 63 | 62 | 41 | 75 | 63 | 1 |
Cullinan Oncology, Inc. | 475.6M | 94 | 72 | 52 | 43 | 98 | 73 | 64 | 1 |
Century Therapeutics, Inc. | 474.8M | 49 | 66 | 49 | 37 | 42 | 53 | 65 | 1 |
Day One Biopharmaceuticals, Inc. | 473.6M | 92 | 75 | 72 | 64 | 74 | 82 | 66 | 1 |
Immunovant, Inc. | 470.2M | 94 | 70 | 77 | 91 | 69 | 83 | 67 | 1 |
Praxis Precision Medicines, Inc. | 462.3M | 95 | 74 | 80 | 61 | 37 | 79 | 68 | 1 |
Inovio Pharmaceuticals, Inc. | 455.8M | 57 | 73 | 60 | 83 | 87 | 74 | 69 | 1 |
Y-mAbs Therapeutics, Inc. | 450.3M | 89 | 74 | 53 | 59 | 77 | 75 | 70 | 1 |
Karyopharm Therapeutics Inc. | 424.1M | 87 | 73 | 55 | 65 | 67 | 74 | 71 | 1 |
IDEAYA Biosciences, Inc. | 404.6M | 76 | 49 | 66 | 85 | 60 | 59 | 72 | 1 |
MeiraGTx Holdings plc | 389.4M | 69 | 69 | 50 | 50 | 51 | 63 | 73 | 1 |
Nuvalent, Inc. | 386.5M | 87 | 71 | 86 | 94 | 74 | 86 | 74 | 1 |
Monte Rosa Therapeutics, Inc. | 380.4M | 87 | 69 | 52 | 73 | 60 | 70 | 75 | 1 |
Repare Therapeutics Inc. | 367.0M | 63 | 72 | 39 | 55 | 82 | 65 | 76 | 1 |
Rallybio Corporation | 352.5M | 56 | 71 | 86 | 92 | 43 | 76 | 77 | 1 |
C4 Therapeutics, Inc. | 348.9M | 79 | 67 | 51 | 40 | 89 | 65 | 78 | 1 |
Arbutus Biopharma Corporation | 343.6M | 90 | 54 | 53 | 67 | 74 | 60 | 79 | 1 |
Generation Bio Co. | 342.5M | 69 | 73 | 48 | 67 | 87 | 72 | 80 | 1 |
Rigel Pharmaceuticals, Inc. | 337.2M | 58 | 74 | 54 | 37 | 80 | 66 | 81 | 1 |
Akero Therapeutics, Inc. | 328.9M | 95 | 75 | 56 | 75 | 98 | 82 | 82 | 1 |
COMPASS Pathways plc | 324.4M | 88 | 75 | 57 | 59 | 46 | 73 | 83 | 1 |
Anika Therapeutics, Inc. | 324.0M | 38 | 70 | 62 | 61 | 49 | 62 | 84 | 1 |
Tenaya Therapeutics, Inc. | 293.3M | 94 | 71 | 78 | 75 | 49 | 79 | 85 | 1 |
Mersana Therapeutics, Inc. | 289.0M | 77 | 72 | 51 | 51 | 90 | 70 | 86 | 1 |
Dyne Therapeutics, Inc. | 288.1M | 96 | 63 | 79 | 54 | 45 | 70 | 87 | 1 |
Precigen, Inc. | 280.4M | 61 | 80 | 57 | 83 | 43 | 75 | 88 | 1 |
AlloVir, Inc. | 264.1M | 86 | 67 | 45 | 78 | 65 | 69 | 89 | 1 |
Lexicon Pharmaceuticals, Inc. | 258.8M | 70 | 73 | 46 | 73 | 69 | 70 | 90 | 1 |
MacroGenics, Inc. | 255.1M | 55 | 73 | 51 | 71 | 51 | 67 | 91 | 1 |
bluebird bio, Inc. | 255.1M | 75 | 74 | 41 | 82 | 85 | 73 | 92 | 1 |
Adaptimmune Therapeutics plc | 228.2M | 57 | 73 | 56 | 51 | 54 | 65 | 93 | 1 |
Cogent Biosciences, Inc. | 186.0M | 89 | 74 | 60 | 59 | 37 | 73 | 94 | 1 |
Acumen Pharmaceuticals, Inc. | 134.9M | 37 | 71 | 77 | 94 | 38 | 70 | 95 | 1 |
Homology Medicines, Inc. | 80.3M | 51 | 72 | 55 | 49 | 59 | 64 | 96 | 1 |
Cabaletta Bio, Inc. | 43.2M | 77 | 73 | 46 | 73 | 47 | 69 | 97 | 1 |
Plumbing BioNTech SE's income statement underlined several specific metrics that typically have the greatest effect on company performance for the upcoming quarter. Specifically, their net income implies excellent execution concerning earnings movement. Statistically, a company's net income can be responsible for up to 34.7% of the probability that the company will beat its benchmark performance. Next, BioNTech SE's cost of sales reveals middle of the road execution with connection to capital expenditure growth. In general, the Company's cost of sales can be responsible for up to 24.3% of the chances of the company to over-perform its benchmark. Looking at BioNTech SE's revenue indicates sub-par sentiment in terms of revenue momentum. Revenue momentum will impact up to 10.4% of the company's likelihood to beat its benchmark performance for the coming months. Bottom line, our evaluation of their income statement deserved the total score of 82.
Parameter | Value | Change | Score |
---|---|---|---|
EBITDA | 10,300.84 | 85% | 97 |
Total Revenues | 13,789.62 | 77% | 39 |
The below chart describes BioNTech SE's performance as reflected on its income statement with respect to its peers. While BioNTech SE received a income statement score of 82 , the average of its peers stands on 64.
Looking into BioNTech SE's cash flow shone a spotlight on several specific factors that provide some of the most meaningful signals into forecasting performance for the coming quarters. First, analysis of the companys flow of cash coming from operations, finance, and investments suggests great in the next quarter overperformance related to cash flow momentum. The flow of cash coming from operations, finance, and investments factors do contribute up to 0.7% of a company's probability to beat the market. Second, the companys net cash flow signals impressive momentum with respect to free cash flow growth. Statistically, these factors influence around 4.9% of the likelihood that a company will beat its benchmark performance throughout the current market. With all factors taken together, their cash flow deserved a total score of 88.
Parameter | Value | Change | Score |
---|---|---|---|
Free Cashflow | 4.92 | 352% | 98 |
Cashflow | 1,402.16 | 311% | 84 |
The below chart describes BioNTech SE's performance as reflected on its cash flow with respect to its peers. While BioNTech SE received a cash flow score of 88, the average of its peers stands on 70.
The combined analyses of these critical factors in the reports makes up our bird's eye view of the company's financial health for the coming quarters. First, the company's metrics in relation to general factors implies mildly disappointing performance in terms of macroeconomic environment. Focusing on looking at the company's health and sustainability conveys solid overperformance related to book value momentum. In general, these factors will contribute up to 24.0% of the company's likelihood to beat the market. Looking at reviewing the company's capital efficiency shows solid momentum related to assets factors momentum. Historically, the capital efficiency factors will impact around 1.0% of the chances of a company to over-perform for the current market. Perhaps most unappreciated, taking in consideration investors' interest suggests weak results related to return factors momentum. Typically, these factors can be responsible for up to 4.1% of a company's likelihood to beat the market in the course of the coming months. In particular, looking closer at BioNTech SE's capital efficiency indicates solid momentum related to assets factors momentum. Statistically, the capital efficiency factors will contribute up to 1.0% of the likelihood that the company will over-perform throughout the coming months. In conclusion, our bottom line grade for their general factors and ratios produced the ranking of 76.
Parameter | Value | Change | Score |
---|---|---|---|
Asset Turnover | 1.76 | 15% | 81 |
Price to Book | 6.61 | -21% | 81 |
Return on Equity | 155.47 | 16% | 45 |
The below chart describes BioNTech SE's performance as reflected on its Financial Ratios with respect to its peers. While BioNTech SE received a Financial Ratios score of 76 , the average of its peers stands on None.
Name | Market Cap | Macro Environment | Book Value Momentum | Return Factors Momentum | Assets Factors Momentum | General Factors | mc_sort | Hidden |
---|---|---|---|---|---|---|---|---|
Amgen Inc. | 130.0B | 44 | 62 | 75 | 48 | 59 | 0 | 1 |
Gilead Sciences, Inc. | 78.2B | 44 | 82 | 58 | 60 | 77 | 1 | 1 |
Regeneron Pharmaceuticals, Inc. | 69.6B | 44 | 84 | 57 | 56 | 78 | 2 | 1 |
Vertex Pharmaceuticals Incorporated | 63.1B | 44 | 75 | 49 | 69 | 69 | 3 | 1 |
Biogen Inc. | 29.2B | 44 | 55 | 78 | 65 | 55 | 4 | 1 |
Seagen Inc. | 25.0B | 44 | 60 | 98 | 58 | 62 | 5 | 1 |
Horizon Therapeutics Public Limited Company | 20.8B | 44 | 88 | 69 | 69 | 85 | 6 | 1 |
Incyte Corporation | 16.6B | 44 | 75 | 39 | 74 | 69 | 7 | 1 |
Alnylam Pharmaceuticals, Inc. | 15.3B | 44 | 58 | 54 | 89 | 57 | 8 | 1 |
BioMarin Pharmaceutical Inc. | 14.4B | 44 | 64 | 48 | 58 | 58 | 9 | 1 |
BeiGene, Ltd. | 13.7B | 44 | 59 | 47 | 63 | 54 | 10 | 1 |
Exact Sciences Corporation | 9.2B | 44 | 52 | 89 | 83 | 57 | 11 | 1 |
United Therapeutics Corporation | 8.3B | 44 | 80 | 73 | 60 | 77 | 12 | 1 |
Neurocrine Biosciences, Inc. | 8.0B | 44 | 78 | 84 | 82 | 80 | 13 | 1 |
Exelixis, Inc. | 6.4B | 44 | 80 | 38 | 80 | 74 | 14 | 1 |
Sarepta Therapeutics, Inc. | 5.8B | 44 | 65 | 46 | 77 | 61 | 15 | 1 |
Halozyme Therapeutics, Inc. | 5.6B | 44 | 78 | 55 | 72 | 74 | 16 | 1 |
Ionis Pharmaceuticals, Inc. | 5.1B | 44 | 50 | 92 | 54 | 52 | 17 | 1 |
Ascendis Pharma A/S | 4.6B | 44 | 84 | 40 | 47 | 74 | 18 | 1 |
Apellis Pharmaceuticals, Inc. | 4.2B | 44 | 78 | 89 | 77 | 80 | 19 | 1 |
Novavax, Inc. | 4.1B | 44 | 56 | 88 | 87 | 61 | 20 | 1 |
Ultragenyx Pharmaceutical Inc. | 3.6B | 44 | 58 | 85 | 84 | 62 | 21 | 1 |
Cytokinetics, Incorporated | 3.6B | 44 | 78 | 56 | 43 | 71 | 22 | 1 |
Arrowhead Pharmaceuticals, Inc. | 3.3B | 44 | 49 | 87 | 88 | 54 | 23 | 1 |
Natera, Inc. | 3.3B | 44 | 78 | 48 | 39 | 68 | 24 | 1 |
Blueprint Medicines Corporation | 3.3B | 44 | 62 | 99 | 39 | 62 | 25 | 1 |
Mirati Therapeutics, Inc. | 3.2B | 44 | 63 | 76 | 78 | 65 | 26 | 1 |
Vir Biotechnology, Inc. | 3.0B | 44 | 79 | 39 | 95 | 75 | 27 | 1 |
ACADIA Pharmaceuticals Inc. | 2.7B | 44 | 56 | 40 | 65 | 51 | 28 | 1 |
PTC Therapeutics, Inc. | 2.3B | 44 | 56 | 52 | 62 | 52 | 29 | 1 |
Insmed Incorporated | 2.2B | 44 | 57 | 81 | 78 | 60 | 30 | 1 |
SpringWorks Therapeutics, Inc. | 1.9B | 44 | 49 | 92 | 88 | 55 | 31 | 1 |
Myriad Genetics, Inc. | 1.8B | 44 | 81 | 63 | 57 | 77 | 32 | 1 |
Ironwood Pharmaceuticals, Inc. | 1.8B | 44 | 82 | 68 | 49 | 77 | 33 | 1 |
BioCryst Pharmaceuticals, Inc. | 1.6B | 44 | 56 | 84 | 94 | 61 | 34 | 1 |
ChemoCentryx, Inc. | 1.4B | 44 | 64 | 69 | 94 | 66 | 35 | 1 |
IVERIC bio, Inc. | 1.2B | 44 | 95 | 46 | 56 | 87 | 36 | 1 |
Agios Pharmaceuticals, Inc. | 1.2B | 44 | 50 | 89 | 93 | 56 | 37 | 1 |
Prometheus Biosciences, Inc. | 1.1B | 44 | 57 | 63 | 60 | 54 | 38 | 1 |
Enanta Pharmaceuticals, Inc. | 1.0B | 44 | 64 | 88 | 87 | 68 | 39 | 1 |
Lyell Immunopharma, Inc. | 982.1M | 44 | 56 | 63 | 74 | 55 | 40 | 1 |
BridgeBio Pharma, Inc. | 977.7M | 44 | 56 | 94 | 87 | 61 | 41 | 1 |
Sana Biotechnology, Inc. | 941.0M | 44 | 58 | 43 | 77 | 54 | 42 | 1 |
FibroGen, Inc. | 927.4M | 44 | 75 | 43 | 80 | 71 | 43 | 1 |
ImmunoGen, Inc. | 844.7M | 44 | 77 | 96 | 53 | 77 | 44 | 1 |
Instil Bio, Inc. | 816.4M | 44 | 56 | 63 | 76 | 56 | 45 | 1 |
Syndax Pharmaceuticals, Inc. | 793.4M | 44 | 60 | 80 | 96 | 64 | 46 | 1 |
Chinook Therapeutics, Inc. | 770.8M | 44 | 53 | 63 | 70 | 52 | 47 | 1 |
Erasca, Inc. | 706.8M | 44 | 98 | 63 | 56 | 92 | 48 | 1 |
Deciphera Pharmaceuticals, Inc. | 705.9M | 44 | 55 | 85 | 94 | 60 | 49 | 1 |
Replimune Group, Inc. | 700.1M | 44 | 50 | 86 | 72 | 53 | 50 | 1 |
Nkarta, Inc. | 678.6M | 44 | 53 | 40 | 74 | 49 | 51 | 1 |
Verve Therapeutics, Inc. | 668.1M | 44 | 50 | 63 | 77 | 50 | 52 | 1 |
Anavex Life Sciences Corp. | 664.9M | 44 | 51 | 87 | 73 | 54 | 53 | 1 |
Gossamer Bio, Inc. | 642.4M | 44 | 58 | 80 | 75 | 59 | 54 | 1 |
IGM Biosciences, Inc. | 619.2M | 44 | 48 | 92 | 72 | 52 | 55 | 1 |
Design Therapeutics, Inc. | 607.9M | 44 | 51 | 63 | 77 | 51 | 56 | 1 |
AnaptysBio, Inc. | 595.6M | 44 | 66 | 37 | 88 | 62 | 57 | 1 |
Sangamo Therapeutics, Inc. | 589.7M | 44 | 47 | 93 | 56 | 49 | 58 | 1 |
Humacyte, Inc. | 553.1M | 69 | 69 | 66 | 67 | 69 | 59 | 1 |
Geron Corporation | 547.3M | 44 | 56 | 79 | 83 | 59 | 60 | 1 |
Intercept Pharmaceuticals, Inc. | 531.3M | 44 | 91 | 42 | 79 | 85 | 61 | 1 |
Bicycle Therapeutics plc | 514.4M | 44 | 91 | 44 | 51 | 82 | 62 | 1 |
Centessa Pharmaceuticals plc | 507.7M | 44 | 48 | 63 | 75 | 48 | 63 | 1 |
Cullinan Oncology, Inc. | 475.6M | 44 | 56 | 74 | 87 | 58 | 64 | 1 |
Century Therapeutics, Inc. | 474.8M | 44 | 53 | 63 | 74 | 52 | 65 | 1 |
Day One Biopharmaceuticals, Inc. | 473.6M | 44 | 62 | 63 | 75 | 61 | 66 | 1 |
Immunovant, Inc. | 470.2M | 44 | 77 | 43 | 61 | 70 | 67 | 1 |
Praxis Precision Medicines, Inc. | 462.3M | 44 | 57 | 78 | 77 | 59 | 68 | 1 |
Inovio Pharmaceuticals, Inc. | 455.8M | 44 | 47 | 89 | 86 | 52 | 69 | 1 |
Y-mAbs Therapeutics, Inc. | 450.3M | 44 | 51 | 78 | 96 | 55 | 70 | 1 |
Karyopharm Therapeutics Inc. | 424.1M | 44 | 56 | 80 | 96 | 61 | 71 | 1 |
IDEAYA Biosciences, Inc. | 404.6M | 44 | 89 | 48 | 54 | 81 | 72 | 1 |
MeiraGTx Holdings plc | 389.4M | 44 | 51 | 92 | 92 | 57 | 73 | 1 |
Nuvalent, Inc. | 386.5M | 44 | 97 | 63 | 56 | 92 | 74 | 1 |
Monte Rosa Therapeutics, Inc. | 380.4M | 44 | 66 | 63 | 72 | 64 | 75 | 1 |
Repare Therapeutics Inc. | 367.0M | 44 | 51 | 92 | 92 | 57 | 76 | 1 |
Rallybio Corporation | 352.5M | 44 | 98 | 63 | 56 | 92 | 77 | 1 |
C4 Therapeutics, Inc. | 348.9M | 44 | 63 | 84 | 87 | 67 | 78 | 1 |
Arbutus Biopharma Corporation | 343.6M | 44 | 74 | 55 | 89 | 72 | 79 | 1 |
Generation Bio Co. | 342.5M | 44 | 56 | 87 | 71 | 58 | 80 | 1 |
Rigel Pharmaceuticals, Inc. | 337.2M | 44 | 55 | 97 | 87 | 61 | 81 | 1 |
Akero Therapeutics, Inc. | 328.9M | 44 | 53 | 41 | 77 | 49 | 82 | 1 |
COMPASS Pathways plc | 324.4M | 44 | 49 | 48 | 75 | 46 | 83 | 1 |
Anika Therapeutics, Inc. | 324.0M | 44 | 68 | 48 | 74 | 64 | 84 | 1 |
Tenaya Therapeutics, Inc. | 293.3M | 44 | 98 | 63 | 56 | 92 | 85 | 1 |
Mersana Therapeutics, Inc. | 289.0M | 44 | 46 | 93 | 93 | 52 | 86 | 1 |
Dyne Therapeutics, Inc. | 288.1M | 44 | 48 | 42 | 77 | 44 | 87 | 1 |
Precigen, Inc. | 280.4M | 44 | 48 | 83 | 81 | 52 | 88 | 1 |
AlloVir, Inc. | 264.1M | 44 | 60 | 42 | 75 | 56 | 89 | 1 |
Lexicon Pharmaceuticals, Inc. | 258.8M | 44 | 63 | 84 | 49 | 62 | 90 | 1 |
MacroGenics, Inc. | 255.1M | 44 | 47 | 82 | 59 | 48 | 91 | 1 |
bluebird bio, Inc. | 255.1M | 44 | 41 | 80 | 92 | 46 | 92 | 1 |
Adaptimmune Therapeutics plc | 228.2M | 44 | 58 | 84 | 87 | 62 | 93 | 1 |
Cogent Biosciences, Inc. | 186.0M | 44 | 57 | 94 | 75 | 61 | 94 | 1 |
Acumen Pharmaceuticals, Inc. | 134.9M | 44 | 97 | 63 | 55 | 91 | 95 | 1 |
Homology Medicines, Inc. | 80.3M | 44 | 53 | 86 | 89 | 58 | 96 | 1 |
Cabaletta Bio, Inc. | 43.2M | 44 | 63 | 72 | 70 | 62 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.